Peptide Therapeutics Market Scenario, Leading Players, Segments Analysis and Forecast to 2024

Share on facebook
Share on twitter
Share on linkedin
North America will be leading the global peptide therapeutics market in the coming years due to high prevalence of chronic diseases, high healthcare expenditure, and high research and development activities.

The global peptide therapeutics market is growing significantly due to the increasing prevalence of cardiovascular diseases and cancer, advances in peptide therapeutics manufacturing technology, and increasing healthcare expenditure. In addition, growing research and development activities along with a rich peptide therapeutics pipeline is expected to support the growth of the peptide therapeutics market. Patent expiration of several peptide drugs in the coming years will create ample opportunities for the global generic peptide therapeutics market to grow at a significant rate in the forecasted period. Peptides are made up of short chains of amino acid monomers. Peptide therapeutics have applications in several indications such as cancer, central nervous system disorders, respiratory disorders, and cardiovascular diseases; this is due to high selectivity, efficacy and safety of peptides.

The advanced research and development facilities and new peptide developments by the pharmaceutical companies are propelling the demand for cost effective peptide therapeutics. However, production of peptides in a large scale with the increasing complexities of peptides is a major challenge for the global peptide therapeutics market. Development of multifunctional peptides and increasing number of collaboration for the development of peptide conjugates are trends in the global peptide therapeutics market.

Request for report sample at: https://www.psmarketresearch.com/market-analysis/peptide-therapeutics-market/report-sample

Some of the factors driving the growth of the global peptide therapeutics market are increasing prevalence of chronic diseases, increasing healthcare expenditure, and increasing investment by pharmaceutical companies for the development of peptide therapeutics. In addition, advancements in peptide manufacturing technology and rich peptide research and development pipeline are propelling the growth of the global peptide therapeutics market. However, stringent regulatory requirements for drug approval, high cost of peptide drugs, and chemical complexities and instability of peptides are some of the factors restraining the growth of the global peptide therapeutics market.

Some of the major players operating in the global peptide therapeutics market are, Sanofi, Teva Pharmaceutical Industries Ltd., Novartis AG, Ipsen S.A., AstraZeneca plc, Amgen Inc., Eli Lilly and Company, Lonza Group Ltd., Merck & Co. Inc., Novo Nordisk A/S, F. Hoffmann-La Roche AG, Bachem Holding AG, PolyPeptide Group, and CordenPharma International GmbH.